Covington Advised AstraZeneca On Acquisition Of EsoBiotec
Covington Advised AstraZeneca On Acquisition Of EsoBiotec
Covington advised AstraZeneca on its definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that have shown promising early clinical activity.
EsoBiotec’s Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers, offering a transformative cell therapy that can be administered in minutes, compared to the weeks-long process of traditional cell therapies. ENaBL uses targeted lentiviruses to deliver Genetic instructions to immune cells, such as T cells, enabling them to recognize and destroy tumor cells for cancer treatment or autoreactive cells for immune-mediated diseases. Unlike conventional approaches, this technology allows cell therapies to be administered via a simple IV injection without the need for immune cell depletion.
The Covington team advising AstraZeneca was led by London partners Gregor Frizzell and Daniel Pavin, with support from Ross Finnie, Babak Hakimian, and Olivia Scalise Gaspar.
